Cited by 1,248Cancer-related Molecular PathwaysCancer Genomics and DiagnosticsGenomics and Rare Diseases

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The IARC TP53 database: New online mutation analysis and recommendations to users

Open access

Olivier, Magali, Eeles, Ros, Hollstein, Monica, Khan, Mohammed A., Harris, Curtis C., Hainaut, Pierre·2002·Human Mutation

DOI 10.1002/humu.10081

Open this paper in CoChat — free account Open PDF

Abstract

Mutations in the tumor suppressor gene TP53 are frequent in most human cancers. Comparison of the mutation patterns in different cancers may reveal clues on the natural history of the disease. Over the past 10 years, several databases of TP53 mutations have been developed. The most extensive of these databases is maintained and developed at the International Agency for Research on Cancer. The database compiles all mutations (somatic and inherited), as well as polymorphisms, that have been reported in the published literature since 1989. The IARC TP53 mutation dataset is the largest dataset available on the variations of any human gene. The database is available at www.iarc.fr/P53/. In this paper, we describe recent developments of the database. These developments include restructuring of the database, which is now patient-centered, with more detailed annotations on the patient (carcinogen exposure, virus infection, genetic background). In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/humu.10081

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53 and Human Cancer: The First Ten Thousand Mutations
Hainaut, P. L., & Hollstein, M. C. (1999) · Advances in cancer research · doi:10.1016/s0065-230x(08)60785-x · Cited by 999
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M. L., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 899
Database of p53 gene somatic mutations in human tumors and cell lines.
Hollstein, M. C., Rice, K., Greenblatt, M. S., Soussi, T., Fuchs, R., Sørlie, T., Hovig, E. J., Smith‐Sørensen, B., Montesano, R., & Harris, C. C. (1994) · Europe PMC (PubMed Central) · Cited by 858
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer
Hussain, S. P., & Harris, C. C. (1999) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s1383-5742(99)00028-9 · Cited by 164
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1993) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(93)90233-c · Cited by 153
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 3

Greenblatt, 1994, Cancer Res, 54, 4855
Hollstein, 1994, Nucleic Acids Res, 22, 3551
Vahteristo, 2001, Cancer Res, 61, 5718

Sorted by citations

Items 301–400 of 1,000

Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study
Kamaraj, B., & Bogaerts, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134638 · Cited by 62
Hyaluronic acid conjugated β-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery
Yin, H. Y., Zhao, F., Zhang, D., & Li, J. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.022 · Cited by 66
Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer
Custodio, A., González-Larriba, J. L., Bobokova, J., Calles, A., Álvarez-Gallego, R., Cuadrado, E., Manzano, A., & Díaz‐Rubio, E. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a4b8fb · Cited by 65
COLD-PCR Enrichment of Rare Cancer Mutations prior to Targeted Amplicon Resequencing
Milbury, C. A., Correll, M., Quackenbush, J. F., Rubio, R., & Makrigiorgos, G. M. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2011.176198 · Cited by 64
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Yu, X., Narayanan, S., Vázquez, A., & Carpizo, D. R. (2014) · APOPTOSIS · doi:10.1007/s10495-014-0990-3 · Cited by 68
UBE2C Is a Transcriptional Target of the Cell Cycle Regulator FOXM1
Nicolau‐Neto, P., Palumbo, A., Martino, M. D., Esposito, F., Simão, T. D. A., Fusco, A., Nasciutti, L. E., Costa, N. M. D., & Pinto, L. F. R. (2018) · Genes · doi:10.3390/genes9040188 · Cited by 66
Investigation of somatic NKX2-5 mutations in congenital heart disease
Draus, J. M., Hauck, M. A., Goetsch, M. A., Austin, E. H., Tomita‐Mitchell, A., & Mitchell, M. E. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.060277 · Cited by 62
Automation of in-silico data analysis processes through workflow management systems
Romano, P. D. (2007) · Briefings in Bioinformatics · doi:10.1093/bib/bbm056 · Cited by 63
Advances in adenovirus-mediated p53 cancer gene therapy
Tazawa, H., Kagawa, S., & Fujiwara, T. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.845662 · Cited by 66
Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas
Kaulich, K., Blaschke, B., Nümann, A., von Deimling, A., Wiestler, O. D., Weber, R. G., & Reifenberger, G. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.12.1092 · Cited by 63
Biomarkers of intermediate endpoints in environmental and occupational health
Knudsen, L. E., & Hansen, Å. M. (2007) · International Journal of Hygiene and Environmental Health · doi:10.1016/j.ijheh.2007.01.015 · Cited by 61
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
Pradhan, M. R., Siau, J. W., Kannan, S., Nguyen, M. N., Ouaray, Z., Kwoh, C. K., Lane, D. P., Ghadessy, F. J., & Verma, C. S. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1314 · Cited by 63
Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells
Honma, M. (2005) · Environmental and Molecular Mutagenesis · doi:10.1002/em.20113 · Cited by 64
ARF1 controls proliferation of breast cancer cells by regulating the retinoblastoma protein
Boulay, P.-L., Schlienger, S., Lewis-Saravalli, S., Vitale, N., Ferbeyre, G., & Claing, A. (2011) · Oncogene · doi:10.1038/onc.2011.100 · Cited by 61
αB‐crystallin: A novel p53‐target gene required for p53‐dependent apoptosis
Watanabe, G., Kato, S., Nakata, H., Ishida, T., Ohuchi, N., & Ishioka, C. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01316.x · Cited by 61
Rb2/p130 is the dominating pocket protein in the p53–p21 DNA damage response pathway leading to senescence
Helmbold, H., Komm, N., Deppert, W., & Bohn, W. (2009) · Oncogene · doi:10.1038/onc.2009.222 · Cited by 63
Polymorphisms in XPD and TP53 and mutation in human lung cancer
Mechanic, L. E. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh344 · Cited by 61
Spontaneous and inherited TP53 genetic alterations
Levine, A. J. (2021) · Oncogene · doi:10.1038/s41388-021-01991-3 · Cited by 67
MDM2: current research status and prospects of tumor treatment
Yao, Y., Zhang, Q., Li, Z., & Zhang, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03356-8 · Cited by 69
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature
Gu, D., Scaringe, W. A., Li, K., Saldivar, J., Hill, K. A., Chen, Z., Hagman, K. D. F., & Sommer, S. S. (2007) · Human Mutation · doi:10.1002/humu.20512 · Cited by 60
PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
Rökaeus, N., Shen, J., Eckhardt, I., Bykov, V. J. N., Wiman, K. G., & Wilhelm, M. (2010) · Oncogene · doi:10.1038/onc.2010.382 · Cited by 59
p53 Is Positively Regulated by miR-542-3p
Wang, Y., Huang, J., Castellà, M., Huntsman, D. D., & Taniguchi, T. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1706 · Cited by 58
Mapping the Structural and Dynamical Features of Multiple p53 DNA Binding Domains: Insights into Loop 1 Intrinsic Dynamics
Lukman, S., Lane, D. P., & Verma, C. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080221 · Cited by 63
Inactivation of the ARF–MDM-2–p53 pathway in sporadic Burkitt's lymphoma in children
Wilda, M., Bruch, J., Harder, L., Rawer, D., Reiter, A., Borkhardt, A., & Woessmann, W. (2003) · Leukemia · doi:10.1038/sj.leu.2403254 · Cited by 59
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
Arlot‐Bonnemains, Y., Baldini, E., Martin, B., Delcros, J., Toller, M., Curcio, F., Ambesi‐Impiombato, F. S., D'Armiento, M., & Ulisse, S. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0021 · Cited by 60
SUMO-1-Dependent Allosteric Regulation of Thymine DNA Glycosylase Alters Subnuclear Localization and CBP/p300 Recruitment
Mohan, R. D., Rao, A., Gagliardi, J., & Tini, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00323-06 · Cited by 59
Genetic variation in TP53 and risk of breast cancer in a population-based case–control study
Sprague, B. L., Trentham‐Dietz, A., García‐Closas, M., Newcomb, P. A., Titus-Ernstoff, L. T., Hampton, J. M., Chanock, S. J., Haines, J. L., & Egan, K. M. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm097 · Cited by 60
Cytochrome P450 1A2 Detoxicates Aristolochic Acid in the Mouse
Rosenquist, T. A., Einolf, H. J., Dickman, K. G., Wang, L., Smith, A., & Grollman, A. P. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.032201 · Cited by 60
Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses
Denzinger, S., Mohren, K., Knuechel, R., Wild, P. J., Burger, M., Wieland, W. F., Hartmann, A., & Stoehr, R. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.10.014 · Cited by 60
Mutant p53-Expressing Cells Undergo Necroptosis via Cell Competition with the Neighboring Normal Epithelial Cells
Watanabe, H., Ishibashi, K., Mano, H., Kitamoto, S., Sato, N., Hoshiba, K., Mugihiko, K., Matsuzawa, F., Takeuchi, Y., Shirai, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.081 · Cited by 64
The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors
López‐Knowles, E., Hernandez, S. F., Kogevinas, M., Lloreta, J., Amorós, À., Tardón, A., Carrato, A., Kishore, S. A., Serra, C., Malats, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0206 · Cited by 60
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma
Li, J., Milbury, C. A., Li, C., & Makrigiorgos, G. M. (2009) · Human Mutation · doi:10.1002/humu.21112 · Cited by 58
Morphologic and molecular analysis of early‐onset gastric cancer
Setia, N., Wang, C. X., Lager, A. M., Maron, S. B., Shroff, S. G., Arndt, N., Peterson, B. F., Kupfer, S. S., Ma, C., Misdraji, J., et al. (2020) · Cancer · doi:10.1002/cncr.33213 · Cited by 58
Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials
Varu, V. N., Tsihlis, N. D., & Kibbe, M. R. (2008) · Vascular and Endovascular Surgery · doi:10.1177/1538574408322752 · Cited by 59
P53 transcriptional activities: A general overview and some thoughts
Millau, J., Bastien, N., & Drouin, R. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.06.002 · Cited by 65
CircRNA–miRNA networks in regulating bone disease
Huang, W., Wu, Y., Qiao, M., Xie, Z., Cen, X. B., Huang, X., & Zhao, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30625 · Cited by 56
Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects
Xu, M., Floyd, H. S., Greth, S. M., Chang, W.-C. J., Lohman, K., Stoyanova, R. S., Kucera, G. L., Kute, T., Willingham, M. C., & Miller, M. S. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.11.013 · Cited by 57
The Role of microRNAs in the Regulation of Apoptosis in Lung Cancer and Its Application in Cancer Treatment
Othman, N., & Nagoor, N. H. (2014) · BioMed Research International · doi:10.1155/2014/318030 · Cited by 57
Sunlight ultraviolet irradiation andBRAFV600 mutagenesis in human melanoma
Nia, A. B., & Pfeifer, G. P. (2008) · Human Mutation · doi:10.1002/humu.20802 · Cited by 60
Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR
Li, J., Wang, L., Janne, P. A., & Makrigiorgos, G. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.113381 · Cited by 57
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer
Koster, R., van Vugt, M. A. T. M., Timmer‐Bosscha, H., Gietema, J. A., & de Jong, S. (2013) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2013.13 · Cited by 58
Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner
Yang, H. J., Zhang, J., Yan, W., Cho, S.-J., Lucchesi, C. A., Chen, M., Huang, E. C., Scoumanne, A., Zhang, W., & Chen, X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711814114 · Cited by 62
An IRAK1–PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy
Liu, P. H., Shah, R. B., Li, Y., Arshi, A., Ung, P. M. U., Raman, R., Gorbatenko, A., Kozono, S., Zhou, X. Z., Brechin, V., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-018-0260-7 · Cited by 53
The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7
Vinall, R. L., Tepper, C. G., Shi, X.-B., Xue, L. A., Gandour‐Edwards, R. F., & White, R. D. (2006) · Oncogene · doi:10.1038/sj.onc.1209246 · Cited by 57
Irradiation-induced Translocation of p53 to Mitochondria in the Absence of Apoptosis
Eßmann, F., Pohlmann, S., Gillissen, B. F., Daniel, P. T., Schulze‐Osthoff, K., & Jänicke, R. U. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502052200 · Cited by 57
Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma
Yan, B., Yang, X., Lee, T., Friedman, J., Tang, J., Waes, C. V., & Chen, Z. (2007) · Genome biology · doi:10.1186/gb-2007-8-5-r78 · Cited by 56
Neuropathy- and myopathy-associated mutations in human small heat shock proteins: Characteristics and evolutionary history of the mutation sites
Benndorf, R., Martin, J. W., Pond, S. L. K., & Wertheim, J. O. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.02.004 · Cited by 56
Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations
Suad, O., Rozenberg, H., Brosh, R., Diskin‐Posner, Y., Kessler, N., Shimon, L. J. W., Frolow, F., Liran, A., Rotter, V., & Shakked, Z. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.10.063 · Cited by 58
Gain of function of mutant p53: R282W on the peak?
Zhang, Y., Coillie, S. V., Fang, J.-Y., & Xu, J. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.8 · Cited by 59
Induced Nitric Oxide Synthase as a Major Player in the Oncogenic Transformation of Inflamed Tissue
Yang, G., Taboada, S., & Liao, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-60327-530-9_8 · Cited by 56
Structural and sequential context of p53: A review of experimental and theoretical evidence
Saha, T., Kar, R. K., & Sa, G. (2014) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2014.12.002 · Cited by 58
Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences
Feldmeyer, N., Schmeiser, H. H., Muehlbauer, K., Belharazem, D., Knyazev, Y. P., Nedelko, T., & Hollstein, M. C. (2006) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2006.02.017 · Cited by 55
Establishment and characterization of 13 human colorectal carcinoma cell lines: mutations of genes and expressions of drug-sensitivity genes and cancer stem cell markers
Ku, J.-L., Shin, Y.-K., Kim, D.-W., Kim, K.-H., Choi, J.-S., Hong, S.-H., Jeon, Y.-K., Kim, S.-H., Kim, H.-S., Park, J.-H., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq043 · Cited by 52
MDM2 Gene Amplification Is Correlated to Tumor Progression but not to the Presence of SNP309 or TP53 Mutational Status in Primary Colorectal Cancers
Forslund, A., Zeng, Z., Qin, L.-X., Rosenberg, S., Ndubuisi, M., Pincas, H., Gerald, W., Notterman, D. A., Barany, F., & Paty, P. B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0239 · Cited by 54
MDM2 Binding Induces a Conformational Change in p53 That Is Opposed by Heat-shock Protein 90 and Precedes p53 Proteasomal Degradation
Sasaki, M. M., Nie, L., & Maki, C. G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610514200 · Cited by 54
The MDM2 Ubiquitination Signal in the DNA-Binding Domain of p53 Forms a Docking Site for Calcium Calmodulin Kinase Superfamily Members
Craig, A. L., Chrystal, J. A., Fraser, J. A., Sphyris, N., Lin, Y., Harrison, B. J., Scott, M. T., Dornreiter, I., & Hupp, T. R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01595-06 · Cited by 52
p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study
Zhang, P., WU, S.-K., Wang, Y., Fan, Z., LI, C.-R., Feng, M., XU, P., Wang, W., & Lang, J. (2014) · Oncology Letters · doi:10.3892/ol.2014.2631 · Cited by 54
A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models
Zhao, Y., Wu, L., Yue, X., Zhang, C., Wang, J., Li, J., Sun, X., Zhu, Y., Feng, Z., & Hu, W. (2018) · eLife · doi:10.7554/elife.34701 · Cited by 54
Transcriptional functionality of germ line p53 mutants influences cancer phenotype
Monti, P., Ciribilli, Y., Jordan, J., Menichini, P., Umbach, D. M., Resnick, M. A., Luzzatto, L., Inga, A., & Fronza, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2545 · Cited by 58
Epigenetic regulation of maspin expression in human ovarian carcinoma cells
Rose, S. L., Fitzgerald, M. P., White, N. O., Hitchler, M. J., Futscher, B. W., Geest, K. D., & Domann, F. E. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.12.025 · Cited by 53
Administration of green tea or caffeine enhances the disappearance of UVB-induced patches of mutant p53 positive epidermal cells in SKH-1 mice
Lu, Y.-P., Lou, Y.-R., Liao, J., Xie, J., Peng, Q.-Y., Yang, C. S., & Conney, A. H. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi086 · Cited by 53
Esophageal Cancer in Golestan Province, Iran: A Review of Genetic Susceptibility and Environmental Risk Factors
Gholipour, M., Islami, F., Roshandel, G., Khoshnia, M., Badakhshan, A., Moradi, A., & Malekzadeh, R. (2016) · Middle East Journal of Digestive Diseases · doi:10.15171/mejdd.2016.34 · Cited by 53
Li–Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53
Zhou, R., Xu, A., Gingold, J. A., Strong, L. C., Zhao, R., & Lee, D. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.07.004 · Cited by 52
Missense Mutations in hMLH1 and hMSH2 Are Associated with Exonic Splicing Enhancers
Gorlov, I. P., Gorlova, O. Y., Frazier, M. L., & Amos, C. I. (2003) · The American Journal of Human Genetics · doi:10.1086/378819 · Cited by 53
Alterations in the p16INK4a and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts
Noble, J. R., Zhong, Z.-H., Neumann, A. A., Melki, J. R., Clark, S. J., & Reddel, R. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207440 · Cited by 53
Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells
Saeed, M. E. M., Jacob, S., Sandjo, L. P., Sugimoto, Y., Khalid, H. E., Opatz, T., Thines, E., & Efferth, T. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00267 · Cited by 53
Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor
Kryštof, V., McNae, I. W., Walkinshaw, M. D., Fischer, P. M., Müller, P., Vojtěšek, B., Orság, M., Havlı́ček, L., & Strnad, M. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5185-1 · Cited by 52
p53-Mediated transactivation of LIMK2b links actin dynamics to cell cycle checkpoint control
Hsu, F.-F., Lin, T.-Y., Chen, J.-Y., & Shieh, S.-Y. (2010) · Oncogene · doi:10.1038/onc.2010.40 · Cited by 55
Gene interaction enrichment and network analysis to identify dysregulated pathways and their interactions in complex diseases
Liu, Y., Koyutürk, M., Barnholtz‐Sloan, J. S., & Chance, M. R. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-65 · Cited by 52
TP53 mutations and SNPs as prognostic and predictive factors in patients with breast cancer (Review)
Huszno, J., & Grzybowska, E. A. (2018) · Oncology Letters · doi:10.3892/ol.2018.8627 · Cited by 52
Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China
Xia, Y., Li, X., & Sun, W. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200731003206 · Cited by 52
The mutational landscape of early‐ and typical‐onset oral tongue squamous cell carcinoma
Campbell, B. R., Chen, Z., Faden, D. L., Agrawal, N., Li, R. J., Hanna, G. J., Iyer, N. G., Boot, A., Rozen, S., Vettore, A. L., et al. (2020) · Cancer · doi:10.1002/cncr.33309 · Cited by 52
Involvement of p53 and p16 Tumor Suppressor Genes in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
Arbiser, J. L., Fan, C., Su, X., Emburgh, B. O. V., Cerimele, F., Miller, M. S., Harvell, J. D., & Marinkovich, M. P. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.23418.x · Cited by 53
Human Pancreatic Carcinoma Cells Activate Maspin Expression Through Loss of Epigenetic Control
Fitzgerald, M. P., Oshiro, M. M., Holtan, N., Krager, K. J., Cullen, J. J., Futscher, B. W., & Domann, F. E. (2003) · Neoplasia · doi:10.1016/s1476-5586(03)80045-3 · Cited by 52
MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population
Lum, S. S., Chua, H. W., Li, H., Li, W., Rao, N., Wei, J., Shao, Z., & Sabapathy, K. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn024 · Cited by 52
HBV DNA integration and HBV‐transcript expression in non‐B, non‐C hepatocellular carcinoma in Japan
Tamori, A., Nishiguchi, S., Kubo, S., Narimatsu, T., Habu, D., Takeda, T., Hirohashi, K., & Shiomi, S. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10514 · Cited by 51
The Pattern of p53 Mutations Caused by PAH o-Quinones is Driven by 8-oxo-dGuo Formation while the Spectrum of Mutations is Determined by Biological Selection for Dominance
Park, J., Gelhaus, S. L., Vedantam, S., Oliva, A. L., Batra, A., Blair, I. A., Troxel, A. B., Field, J. M., & Penning, T. M. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700404a · Cited by 51
Mutational Analysis of the p53 Core Domain L1 Loop
Zupnick, A., & Prives, C. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603387200 · Cited by 51
Deregulation of SYCP 2 predicts early stage human papillomavirus‐positive oropharyngeal carcinoma: A prospective whole transcriptome analysis
Masterson, L. M., Sorgeloos, F., Winder, D. M., Lechner, M., Marker, A. J., Malhotra, S., Sudhoff, H. H., Jani, P., Goon, P. K. C., & Sterling, J. C. (2015) · Cancer Science · doi:10.1111/cas.12809 · Cited by 53
p53 and p73 display common and distinct requirements for sequence specific binding to DNA
Lokshin, M., Li, Y., Gaiddon, C., & Prives, C. L. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1047 · Cited by 55
Choosing where to look next in a mutation sequence space: Active Learning of informative p53 cancer rescue mutants
Danziger, S. A., Zeng, J., Wang, Y., Brachmann, R. K., & Lathrop, R. H. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm166 · Cited by 51
Biowep: a workflow enactment portal for bioinformatics applications
Romano, P. D., Bartocci, E., Bertolini, G., Paoli, F. D., Marra, D., Mauri, G., Merelli, E., & Milanesi, L. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-s1-s19 · Cited by 51
Combination of doxorubicin-based chemotherapy and polyethylenimine/p53 gene therapy for the treatment of lung cancer using porous PLGA microparticles
Shi, X., Li, C., Gao, S., Zhang, L., Han, H., Zhang, J., Shi, W., & Li, Q. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.07.020 · Cited by 50
Oral cancer databases: A comprehensive review
Sarode, G. S., Sarode, S. C., Maniyar, N., Anand, R., & Patil, S. V. (2017) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12667 · Cited by 51
High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling
Bastien, R. R. L., Lewis, T. B., Hawkes, J. E., Quackenbush, J. F., Robbins, T. C., Palazzo, J., Perou, C. M., & Bernard, P. S. (2008) · Human Mutation · doi:10.1002/humu.20726 · Cited by 50
DNA-based biosensor platforms for the detection of TP53 mutation
Altıntaş, Z., & Tothill, I. E. (2012) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2012.04.064 · Cited by 49
Interferon‐inducible guanylate binding protein (GBP)‐2: A novel p53‐regulated tumor marker in esophageal squamous cell carcinomas
Guimarães, D. P., de Oliveira, I. M., de Moraes, E., Silva, G. R. D. P., de Souza, D. M., Barnas, C., Olmedo, D. B., Pinto, C. E., de Faria, P. A. S., Gallo, C. V. D. M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23944 · Cited by 49
From mutational inactivation to aberrant gain‐of‐function: Unraveling the structural basis of mutant p53 oncogenic transition
Olotu, F. A., & Soliman, M. E. S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26430 · Cited by 51
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cells
Logan, I. R., McNeill, H. V., Cook, S., Lü, X., Lunec, J., & Robson, C. N. (2007) · The Prostate · doi:10.1002/pros.20568 · Cited by 49
RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses
Saha, M. N., Jiang, H., Mukai, A., & Chang, H. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0471 · Cited by 48
MEF immortalization to investigate the ins and outs of mutagenesis
Brocke, J. V., Schmeiser, H. H., Reinbold, M., & Hollstein, M. C. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl101 · Cited by 51
Frequent Mutations in EGFR, KRAS and TP53 Genes in Human Lung Cancer Tumors Detected by Ion Torrent DNA Sequencing
Cai, X., Sheng, J., Tang, C., Nandakumar, V., Ye, H., Ji, H. L., Tang, H., Yu, Q., Guan, H., Lou, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095228 · Cited by 47
The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US caucasian women
Han, J., Cox, D. G., Colditz, G. A., & Hunter, D. J. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20190 · Cited by 47
ID1, Inhibitor of Differentiation/DNA Binding, Is an Effector of the p53-dependent DNA Damage Response Pathway
Qian, Y., & Chen, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800643200 · Cited by 49
Cellular and Molecular Targets of Protein S -Glutathiolation
Shackelford, R. E., Heinloth, A. N., Heard, S. C., & Paules, R. S. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.940 · Cited by 47
The p53 knowledgebase: an integrated information resource for p53 research
Lim, Y.-P., Lim, T. T., Chan, Y. L., Song, A. C. M., Yeo, B. H., Vojtĕsek, B., Coomber, D., Rajagopal, G., & Lane, D. P. (2006) · Oncogene · doi:10.1038/sj.onc.1209952 · Cited by 47
Breast-Cancer Stromal Cells withTP53Mutations
Campbell, I. G., Qiu, W., Polyák, K., & Haviv, I. (2008) · New England Journal of Medicine · doi:10.1056/nejmc086024 · Cited by 47
p53 regulates the mevalonate pathway in human glioblastoma multiforme
Laezza, C., D’Alessandro, A., Croce, L. D., Picardi, P., Ciaglia, E., Pisanti, S., Malfitano, A. M., Comegna, M., Faraonio, R., Gazzerro, P., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.279 · Cited by 47
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma
Smardova (2010) · International Journal of Oncology · doi:10.3892/ijo_00000545 · Cited by 46

Authors: Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P.
Affiliations: World Health Organization (CH)
German Cancer Research Center (DE)
National Institutes of Health (US)
Corresponding author: Hainaut, Pierre
ORCID: Olivier, Magali
Harris, Curtis C.
Hainaut, Pierre
Venue: Human Mutation
Publisher: Wiley
Published: 2002-05-03
Volume: 19
Issue: 6
Pages: 607-614
ISSN: 1059-7794 (ISSN-L)
1098-1004
DOI: 10.1002/humu.10081
OpenAlex: W2073576377
Cited by: 1,248
References: 14
Citations by year: 2026: 11 · 2025: 20 · 2024: 33 · 2023: 46 · 2022: 33 · 2021: 33 · 2020: 32 · 2019: 31 · 2018: 40 · 2017: 30 · 2016: 37 · 2015: 34 · 2014: 48 · 2013: 43 · 2012: 61
FWCI: 29.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4869 d)
Locations: Human Mutation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords: TP53 mutation, somatic mutations, TP53 polymorphisms, mutation patterns, cancer genomics, carcinogen exposure, viral infection, genetic background, database restructuring
MeSH terms: DNA Mutational Analysis, Humans, Mutation, Genes, Tumor Suppressor, Genes, p53, Li-Fraumeni Syndrome, Computational Biology, Internet, Databases, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The IARC TP53 database: New online mutation analysis and recommendations to users

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks